Latest Blood disorders Stories
CAMBRIDGE, Mass., July 10, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that the agency has placed a clinical hold on clinical trials evaluating the safety and efficacy of IB1001, an intravenous recombinant factor IX (rFIX) being investigated for the treatment and prevention of bleeding episodes in people with hemophilia B. The clinical hold impacts two ongoing...
WOODCLIFF LAKE, N.J., July 9, 2012 /PRNewswire/ -- Eisai Inc. today announced preliminary results from a recently completed phase III study of Halaven versus capecitabine (Xeloda®) in women with locally advanced or metastatic breast cancer. The trial did not meet the pre-specified criteria for either of the co-primary endpoints of overall survival (OS) and progression-free survival (PFS). The study did show, however, a trend toward improved OS for patients who received Halaven...
WHITE PLAINS, N.Y., July 9, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society's (LLS) 2012 Man & Woman of the Year campaign exceeded last year's record-breaking year, raising $18.9 million for blood cancer research and patient services. In its 22nd year more than 800 candidates participated and surpassed last year's fundraising record by $4.2 million. Out of all those candidates, one man, Washington D.C. leukemia survivor Tommy Cleaver, and one woman, St. Louis based...
WHITE PLAINS, N.Y., July 9, 2012 /PRNewswire/ -- Over the past decade, Burlington Coat Factory has raised close to $13 million through its company-wide initiative encouraging its customers to purchase paper balloon icons as a donation to The Leukemia & Lymphoma Society (LLS) to help fund cancer research and patient services, Today, Burlington Coat Factory, LLS's #1 National Corporate Light The Night(®) Walk partner, announced the launch of its 11th year in support of the...
SAN DIEGO, July 9, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has received Investigational Review Board (IRB) approval at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center for a Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of cutaneous T-cell...
PARIS, July 9, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds. Edward Gomperts, MD,...
WAYNE, N.J., July 8, 2012 /PRNewswire/ -- Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A. The PROTECT VIII (PROphylaxis in hemophilia A patienTs via directly pEgylated long-aCTing rFVIII) trial is designed to investigate whether BAY94-9027, a recombinant human factor VIII (rFVIII), can prolong the duration of protection from...
New study “Global Hemophilia Market Report: 2012 Edition” developed by Koncept Analytics has been recently published by Market Publishers Ltd. According to the study, the global market for hemophilia products has shown continuous growth in the past years growing at 8.96% CAGR from 2006 to 2011 and is projected to expand steadily in the upcoming years. London, UK (PRWEB) July 06, 2012 The global market for hemophilia products has shown continuous growth in the past years growing at...
Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all standard therapies. About one-third of aplastic anemia cases do not respond to standard therapy, a combination of immune-suppressing drugs. Although bone marrow stem cell transplantation is an option for some, patients without a matched donor have few treatment options....
YPSILANTI, Mich., July 3, 2012 /PRNewswire-USNewswire/ -- The Hemophilia Foundation of Michigan (HFM) has named its Michigan Legislators of the Year. The annual awards, which recognize excellence in legislative policy making affecting the bleeding disorders community, were announced at HFM's annual consumer conference. Presenting the legislative awards, Hemophilia Foundation of Michigan Executive Director, Ivan Harner, noted, "Senator Tonya Schuitmaker recognizes the life long...
